Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors.

Coletta AM, Marquez G, Thomas P, Thoman W, Bevers T, Brewster AM, Hawk E, Basen-Engquist K, Gilchrist SC.

PLoS One. 2019 Aug 1;14(8):e0220814. doi: 10.1371/journal.pone.0220814. eCollection 2019.

2.

High-Intensity Interval Training is Feasible in Women at High Risk for Breast Cancer.

Coletta AM, Brewster AM, Chen M, Li Y, Bevers TB, Basen-Engquist K, Gilchrist SC.

Med Sci Sports Exerc. 2019 Jun 20. doi: 10.1249/MSS.0000000000002048. [Epub ahead of print]

PMID:
31269007
3.

Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812).

Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser M, Goodman GE, Brown PH.

Cancer Prev Res (Phila). 2019 Jul;12(7):481-490. doi: 10.1158/1940-6207.CAPR-18-0444. Epub 2019 May 28.

PMID:
31138522
4.

Supplemental ultrasound screening in patients with a history of lobular neoplasia.

Phalak KA, Milton DR, Yang WT, Bevers TB, Dogan BE.

Breast J. 2019 Mar;25(2):250-256. doi: 10.1111/tbj.13191. Epub 2019 Jan 24.

PMID:
30675929
5.

Screening Mammography for Average-Risk Women: The Controversy and NCCN's Position.

Helvie MA, Bevers TB.

J Natl Compr Canc Netw. 2018 Nov;16(11):1398-1404. doi: 10.6004/jnccn.2018.7081. Review.

PMID:
30442738
6.

Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, Garber JE, Gray R, Greenberg CC, Greenup R, Hansen NM, Harris RE, Heerdt AS, Helsten T, Hodgkiss L, Hoyt TL, Huff JG, Jacobs L, Lehman CD, Monsees B, Niell BL, Parker CC, Pearlman M, Philpotts L, Shepardson LB, Smith ML, Stein M, Tumyan L, Williams C, Bergman MA, Kumar R.

J Natl Compr Canc Netw. 2018 Nov;16(11):1362-1389. doi: 10.6004/jnccn.2018.0083.

PMID:
30442736
7.

Randomized trial of a patient-centered decision aid for promoting informed decisions about lung cancer screening: Implementation of a PCORI study protocol and lessons learned.

Lowenstein LM, Escoto KH, Leal VB, Bailey L, Bevers TB, Cantor SB, Cinciripini PM, Jacobs LE, Esparza A, Godoy MC, Housten AJ, Lin H, Luckett P, Munden RF, Rabius V, Volk RJ.

Contemp Clin Trials. 2018 Sep;72:26-34. doi: 10.1016/j.cct.2018.07.007. Epub 2018 Jul 20.

8.

A System-Level Approach to Improve the Uptake of Antiestrogen Preventive Therapy among Women with Atypical Hyperplasia and Lobular Cancer In Situ.

Brewster AM, Thomas P, Brown P, Coyne R, Yan Y, Checka C, Middleton L, Do KA, Bevers T.

Cancer Prev Res (Phila). 2018 May;11(5):295-302. doi: 10.1158/1940-6207.CAPR-17-0314. Epub 2018 Apr 4.

9.

Resistance to discontinuing breast cancer screening in older women: A qualitative study.

Housten AJ, Pappadis MR, Krishnan S, Weller SC, Giordano SH, Bevers TB, Volk RJ, Hoover DS.

Psychooncology. 2018 Jun;27(6):1635-1641. doi: 10.1002/pon.4708. Epub 2018 Apr 17.

10.

Preferences for Communicating about Breast Cancer Screening Among Racially/Ethnically Diverse Older Women.

Hoover DS, Pappadis MR, Housten AJ, Krishnan S, Weller SC, Giordano SH, Bevers TB, Goodwin JS, Volk RJ.

Health Commun. 2019 Jun;34(7):702-706. doi: 10.1080/10410236.2018.1431026. Epub 2018 Jan 26.

PMID:
29373069
11.

Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.

Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC.

Fam Cancer. 2018 Apr;17(2):287-294. doi: 10.1007/s10689-017-0034-6.

PMID:
28988289
12.

NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction.

Holmberg C, Bandos H, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens WJ.

Cancer Prev Res (Phila). 2017 Nov;10(11):625-634. doi: 10.1158/1940-6207.CAPR-17-0076. Epub 2017 Oct 4.

13.

Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study.

Blakeslee SB, McCaskill-Stevens W, Parker PA, Gunn CM, Bandos H, Bevers TB, Battaglia TA, Fagerlin A, Müller-Nordhorn J, Holmberg C.

Patient Educ Couns. 2017 Dec;100(12):2346-2354. doi: 10.1016/j.pec.2017.06.033. Epub 2017 Jun 27.

14.

Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.

Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL Jr, Sneige N, Gong Y, Bevers TB.

Cancer Cytopathol. 2017 Aug;125(8):644-651. doi: 10.1002/cncy.21877. Epub 2017 May 12.

15.

Mammographic breast density is associated with the development of contralateral breast cancer.

Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M Jr, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH.

Cancer. 2017 Jun 1;123(11):1935-1940. doi: 10.1002/cncr.30573. Epub 2017 Jan 30.

16.

Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment.

Krishnamurthy S, Bevers T, Kuerer HM, Smith B, Yang WT.

AJR Am J Roentgenol. 2017 Feb;208(2):248-255. doi: 10.2214/AJR.16.17130. Epub 2016 Dec 8. Review.

17.

Clinical Approach for Patient-Centered Physical Activity Assessment and Interventions.

Austin A, Damani S, Bevers T.

Clin J Oncol Nurs. 2016 Dec 1;20(6 Suppl):S2. Review.

PMID:
27857272
18.

Effect of routine screening for sexual problems in a breast cancer survivorship clinic.

Bradford A, Fellman B, Urbauer D, Bevers T.

Psychooncology. 2016 Nov;25(11):1375-1378. doi: 10.1002/pon.3999. Epub 2015 Oct 9. No abstract available.

19.

Long-Term Safety of Observation in Selected Women Following Core Biopsy Diagnosis of Atypical Ductal Hyperplasia.

Menen RS, Ganesan N, Bevers T, Ying J, Coyne R, Lane D, Albarracin C, Bedrosian I.

Ann Surg Oncol. 2017 Jan;24(1):70-76. doi: 10.1245/s10434-016-5512-9. Epub 2016 Aug 29.

20.

A brief measure of Smokers' knowledge of lung cancer screening with low-dose computed tomography.

Lowenstein LM, Richards VF, Leal VB, Housten AJ, Bevers TB, Cantor SB, Cinciripini PM, Cofta-Woerpel LM, Escoto KH, Godoy MC, Linder SK, Munden RF, Volk RJ.

Prev Med Rep. 2016 Jul 26;4:351-6. doi: 10.1016/j.pmedr.2016.07.008. eCollection 2016 Dec.

21.

Controversies in Breast Cancer Screening Strategies.

Bevers T, Bibbins-Domingo K, Oeffinger KC, Smith ML.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):651-3.

PMID:
27226505
22.

Clinical Breast Examination and Breast Cancer Screening Guideline.

Anderson BO, Bevers TB, Carlson RW.

JAMA. 2016 Apr 5;315(13):1403-4. doi: 10.1001/jama.2016.0686. No abstract available.

PMID:
27046372
23.

Epidemiological risk factors associated with inflammatory breast cancer subtypes.

Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM.

Cancer Causes Control. 2016 Mar;27(3):359-66. doi: 10.1007/s10552-015-0712-3. Epub 2016 Jan 21.

24.

User Perceptions and Reactions to an Online Cancer Risk Assessment Tool: a Process Evaluation of Cancer Risk Check.

Hovick SR, Bevers TB, Vidrine JI, Kim S, Dailey PM, Jones LA, Peterson SK.

J Cancer Educ. 2017 Mar;32(1):141-147. doi: 10.1007/s13187-015-0939-4.

25.

Chemoprevention for Breast Cancer.

Pruthi S, Heisey RE, Bevers TB.

Ann Surg Oncol. 2015 Oct;22(10):3230-5. doi: 10.1245/s10434-015-4715-9. Epub 2015 Jul 23.

26.

Breast Cancer Risk Reduction, Version 2.2015.

Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.

J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.

PMID:
26150582
27.

Breast cancer risk reduction therapy: the low-hanging fruit.

Bevers TB.

J Natl Compr Canc Netw. 2015 Apr;13(4):376-8. No abstract available.

PMID:
25870373
28.

Personalized assessment and management of women at risk for breast cancer in North America.

Pruthi S, Heisey R, Bevers T.

Womens Health (Lond). 2015 Mar;11(2):213-23; quiz 223-4. doi: 10.2217/whe.14.79. Review. Erratum in: Womens Health (Lond). 2016 Jun;12 (3):390.

PMID:
25776295
29.

Should CMS cover lung cancer screening for the fully informed patient?

Volk RJ, Hawk E, Bevers TB.

JAMA. 2014 Sep 24;312(12):1193-4. doi: 10.1001/jama.2014.12709. No abstract available.

30.

Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer.

Crew KD, Ho KA, Brown P, Greenlee H, Bevers TB, Arun B, Sneige N, Hudis C, McArthur HL, Chang J, Rimawi M, Cornelison TL, Cardelli J, Santella RM, Wang A, Lippman SM, Hershman DL.

J Hum Nutr Diet. 2015 Jun;28(3):272-82. doi: 10.1111/jhn.12229. Epub 2014 Mar 19.

31.

Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting.

Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P, Bevers TB.

Cancer Med. 2014 Jun;3(3):492-9. doi: 10.1002/cam4.223. Epub 2014 Mar 18.

32.

Feasibility of a patient decision aid about lung cancer screening with low-dose computed tomography.

Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB.

Prev Med. 2014 May;62:60-3. doi: 10.1016/j.ypmed.2014.02.006. Epub 2014 Feb 8.

33.

An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis.

Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM.

Biomark Cancer. 2013 Nov 19;5:71-80. doi: 10.4137/BIC.S13236. eCollection 2013.

34.

Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision.

Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL Jr, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L.

Clin Breast Cancer. 2013 Dec;13(6):439-49. doi: 10.1016/j.clbc.2013.08.007. Epub 2013 Oct 8.

35.

A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.

Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC Jr.

Cancer. 2013 Oct 1;119(19):3454-61. doi: 10.1002/cncr.28183. Epub 2013 Aug 26.

36.

Brain responses to erotic and other emotional stimuli in breast cancer survivors with and without distress about low sexual desire: a preliminary fMRI study.

Versace F, Engelmann JM, Jackson EF, Slapin A, Cortese KM, Bevers TB, Schover LR.

Brain Imaging Behav. 2013 Dec;7(4):533-42. doi: 10.1007/s11682-013-9252-1.

37.

The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results.

Guo M, Gong Y, Wang J, Dawlett M, Patel S, Liu P, Bevers TB, Sneige N.

Cancer Cytopathol. 2013 Feb;121(2):79-85. doi: 10.1002/cncy.21240. Epub 2012 Dec 5.

38.

The evolution of breast self-examination to breast awareness.

Mac Bride MB, Pruthi S, Bevers T.

Breast J. 2012 Nov-Dec;18(6):641-3. doi: 10.1111/tbj.12023. Epub 2012 Sep 26. No abstract available.

PMID:
23009674
39.

Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.

Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, McArthur HL, Chang J, Rimawi M, Vornik L, Cornelison TL, Wang A, Hibshoosh H, Ahmed A, Terry MB, Santella RM, Lippman SM, Hershman DL.

Cancer Prev Res (Phila). 2012 Sep;5(9):1144-54. doi: 10.1158/1940-6207.CAPR-12-0117. Epub 2012 Jul 24.

40.

Exemestane in the prevention setting.

Litton JK, Bevers TB, Arun BK.

Ther Adv Med Oncol. 2012 May;4(3):107-12. doi: 10.1177/1758834012438214.

41.

Multidisciplinary considerations in the management of high-risk breast lesions.

Krishnamurthy S, Bevers T, Kuerer H, Yang WT.

AJR Am J Roentgenol. 2012 Feb;198(2):W132-40. doi: 10.2214/AJR.11.7799. Review.

PMID:
22268202
42.

The results of a breast cancer screening cAMP at a district level in rural India.

Reddy N, Ninan T, Tabar L, Bevers T.

Asian Pac J Cancer Prev. 2012;13(12):6067-72.

43.

Breast cancer prevention: an update of the STAR trial.

Bevers TB.

Curr Treat Options Oncol. 2010 Dec;11(3-4):66-9. doi: 10.1007/s11864-010-0124-2. No abstract available.

PMID:
21061192
44.

Breast cancer risk reduction.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH.

J Natl Compr Canc Netw. 2010 Oct;8(10):1112-46. No abstract available.

PMID:
20971838
45.

A nomogram to predict for malignant diagnosis of BI-RADS Category 4 breast lesions.

Mazouni C, Sneige N, Rouzier R, Balleyguier C, Bevers T, André F, Vielh P, Delaloge S.

J Surg Oncol. 2010 Sep 1;102(3):220-4. doi: 10.1002/jso.21616.

PMID:
20740578
46.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

47.

Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition.

Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM.

J Womens Health (Larchmt). 2010 Mar;19(3):371-9. doi: 10.1089/jwh.2009.1605.

48.

NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.

Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Nov;7(10):1060-96. Review. No abstract available. Erratum in: J Natl Compr Canc Netw. 2010 Feb;8(2):xxxvii. Buys, Sandra [corrected to Buys, Saundra]; Yaneeklov, Thomas [corrected to Yankeelov, Thomas].

PMID:
19930975
49.

Breast awareness: a shift in the paradigm of breast self-examination.

Bevers TB.

J Natl Compr Canc Netw. 2009 Nov;7(10):1042-3. No abstract available.

PMID:
19930973
50.

Alcohol and cancer incidence in women.

Bevers TB.

Curr Oncol Rep. 2009 Nov;11(6):417-20. No abstract available.

PMID:
19840518

Supplemental Content

Loading ...
Support Center